Avita gets more US army funds for ReCell trial
28 September, 2012 by Dylan Bushell-EmblingAvita Medical (ASX:AVH) has secured additional funding from the US Department of Defense to support the FDA trial for its ReCell Spray-On-Skin in burn injuries.
NZP to produce drug for NIH trial
28 September, 2012 by Dylan Bushell-EmblingNew Zealand Pharmaceuticals (NZP) has announced it will be involved in a phase I trial treating rare genetic disease Hereditary Inclusion Body Myopathy (HIBM) launched by the US National Institutes of Health (NIH).
Kinomics research centre to develop next generation drugs
28 September, 2012 by Tim DeanA new dual-site research centre focusing on kinomics is now open for business, focusing on developing new drugs to battle cancer and other diseases.
CSL near diabetes breakthrough
27 September, 2012 by Dylan Bushell-EmblingA drug candidate developed by CSL (ASX:CSL) which blocks the protein VEGF-B prevented the development or progression of type-2 diabetes in three separate animal trials.
Government proposes “tough new standards” for Innovation Patents
27 September, 2012 by AusBiotechThe Federal Government said in media release this week that it is “considering tough new standards for Innovation Patents in order to discourage large companies from abusing the IP system.”
AusBiotech urges Business Tax Working Group to leave R&D Tax Incentive intact
25 September, 2012 by AusBiotechAusBiotech has made a submission to Treasury’s Business Tax Working Group (BTWG) in response to its recent discussion paper suggesting that the 40% offset of the newly implemented R&D Tax Incentive be targeted for removal or reduction.
Comment: Genetically modified corn and cancer – what does the evidence really say?
25 September, 2012 by Staff WritersFrench scientist Gilles-Eric Seralini caused quite a stir last week when he claimed he’d shown cancer in rats increased when they were fed genetically modified corn and/or water spiked with the herbicide Roundup. The paper, which seven of his colleagues co-authored, was published in the peer-reviewed journal Food and Chemical Toxicology.
Alchemia spending to boost fondaparinux profits
24 September, 2012 by Dylan Bushell-EmblingAlchemia (ASX:ACL) has revealed an extra $10 million investment to reduce production costs and maximise profits after acknowledging that market competition has delayed the profitability of generic fondaparinux in the US.
Government considering tightening innovation patents
24 September, 2012 by Tim DeanThe government has invited comment from the public on “tough new” amendments to intellectual property laws to tighten up innovation patents.
EndoBarrier on offer at two Australian clinics
24 September, 2012 by Dylan Bushell-EmblingGI Dynanics (ASX:GID) continues rollout of its EndoBarrier in Australia with it now offering the weight loss and diabetes treatment in two additional locations, St Vincent's Clinic and Macquarie University Hospital.
Avita's US trials may hold key to ReCell adoption
21 September, 2012 by Dylan Bushell-EmblingMajor US clinical trials of Avita Medical's (ASX:AVH) ReCell spray-on skin could provide the impetus needed to stimulate adoption of the technology in the medical community, a recent report suggests.
Patrys cleared for multiple myeloma trial
20 September, 2012 by Dylan Bushell-EmblingPatrys (ASX:PAB) plans to commence a phase I/IIb trial of anti-tumour antibody PAT-SM6 in Germany in Q4, after getting the go-ahead from regulators.
Presenting companies announced for major investment summit
20 September, 2012 by AusBiotechThe Australasian Life Science Investment Summit 2012, the largest investment event of its kind in the Southern Hemisphere will again be held in conjunction with Australia’s premier biotechnology industry conference, AusBiotech 2012. Companies selected to present at the event have been announced.
Government freeze on grants raises concern in biotech sector
19 September, 2012 by Tim DeanThe life science sector is increasingly concerned over an indefinite freeze which has been placed on federal government grants that support innovation. The freeze is not only preventing funds from flowing through to companies that have lodged applications, but the uncertainty over the nature and implications of the freeze is causing some to fear that certain grants may be cut.
Avexa still in the HIV game
19 September, 2012 by Dylan Bushell-EmblingAvexa is still working on developing next generation treatments for HIV following a turbulent couple of years, including the dumping of board in 2010 which ceased development of its lead HIV drug apcicitabine (ATC).
